Ping Zhang

CIK: 0002050176

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

GYRE

GYRE THERAPEUTICS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

GYRE
GYRE THERAPEUTICS, INC.
May 14, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
250K shares-
GYRE
GYRE THERAPEUTICS, INC.
Jan 7, 2026
Award(A)
Stock Option (Right to Buy)
Direct
100K shares-
GYRE
GYRE THERAPEUTICS, INC.
Aug 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
250K shares-
GYRE
GYRE THERAPEUTICS, INC.
May 27, 2025
Award(A)
Stock Option (Right to Buy)
Direct
250K shares-
GYRE
GYRE THERAPEUTICS, INC.
Jan 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
52K shares-

		Type	Shares	Price		Ownership
May 14, 2026	GYRE GYRE THERAPEUTICS, INC.	Disposition(D) Stock Option (Right to Buy)	250,000	-	-	Direct
Jan 7, 2026	GYRE GYRE THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	100,000	-	-	Direct
Aug 5, 2025	GYRE GYRE THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	250,000	-	-	Direct
May 27, 2025	GYRE GYRE THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	250,000	-	-	Direct
Jan 5, 2025	GYRE GYRE THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	52,000	-	-	Direct

1-5 of 5 transactions

About Zhang Ping

Zhang Ping (SEC CIK 0002050176) files insider reports with the SEC as Director of GYRE THERAPEUTICS, INC. (GYRE).

Signal8 holds 6 ownership filings by Zhang Ping (1 Form 3, 5 Form 4), filed between Jan 7, 2025 and May 20, 2026. Those filings report 5 transactions, from Jan 5, 2025 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Zhang Ping's filings is in SAN DIEGO, CA.

Recent filings by Zhang Ping

May 14, 2026: Disposition to issuer transaction of GYRE derivative securities (Form 4, code D).
Jan 7, 2026: Grant or award of GYRE derivative securities (Form 4, code A).
Aug 5, 2025: Grant or award of GYRE derivative securities (Form 4, code A).
May 27, 2025: Grant or award of GYRE derivative securities (Form 4, code A).
Jan 5, 2025: Grant or award of GYRE derivative securities (Form 4, code A).

Other insiders filing for GYRE THERAPEUTICS, INC. (GYRE)

Weston Claire, Director
Kirkby Maxwell, Director
Ye Weiguo, Chief Operating Officer
Bergmann Joshua Benjamin, GC and Corporate Secretary
Luo Ying, Chief Executive Officer
Wang Jialiang (NMN), EVP, General Manager

How to read Form 4 transaction codes